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Abstract
Cigarette smoking is the main risk factor for COPD (Chronic Obstructive Pulmonary Disease), yet only a subset of smokers
develops COPD. Family members of patients with severe early-onset COPD have an increased risk to develop COPD and are
therefore defined as ‘‘susceptible individuals’’. Here we perform unbiased analyses of proteomic profiles to assess how
‘‘susceptible individuals’’ differ from age-matched ‘‘non-susceptible individuals’’ in response to cigarette smoking. Epithelial
lining fluid (ELF) was collected at baseline and 24 hours after smoking 3 cigarettes in young individuals susceptible or non-
susceptible to develop COPD and older subjects with established COPD. Controls at baseline were older healthy smoking
and non-smoking individuals. Five samples per group were pooled and analysed by stable isotope labelling (iTRAQ) in
duplicate. Six proteins were selected and validated by ELISA or immunohistochemistry. After smoking, 23 proteins increased
or decreased in young susceptible individuals, 7 in young non-susceptible individuals, and 13 in COPD in the first
experiment; 23 proteins increased or decreased in young susceptible individuals, 32 in young non-susceptible individuals,
and 11 in COPD in the second experiment. SerpinB3 and Uteroglobin decreased after acute smoke exposure in young non-
susceptible individuals exclusively, whereas Peroxiredoxin I, S100A9, S100A8, ALDH3A1 (Aldehyde dehydrogenase 3A1)
decreased both in young susceptible and non-susceptible individuals, changes being significantly different between groups
for Uteroglobin with iTRAQ and for Serpin B3 with iTRAQ and ELISA measures. Peroxiredoxin I, SerpinB3 and ALDH3A1
increased in COPD patients after smoking. We conclude that smoking induces a differential protein response in ELF of
susceptible and non-susceptible young individuals, which differs from patients with established COPD. This is the first study
applying unbiased proteomic profiling to unravel the underlying mechanisms that induce COPD. Our data suggest that
SerpinB3 and Uteroglobin could be interesting proteins in understanding the processes leading to COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a major
leading chronic disease and the only one with increasing
prevalence and mortality worldwide. It is characterized by
chronic, progressive airflow limitation [1]. The pathology of
COPD includes a complex network of inflammation, oxidative
stress, tissue damage, remodelling and repair [2]. It comprises
many detrimental processes that contribute to disease progression,
a progression that is relentless and without a cure. Further
research in this area is thus important, since a better understand-
ing of COPD pathogenesis will enable the development of new
and more effective treatments for the prevention and progression
of COPD. Proteomics is an emerging scientific research field with
important advances in proteomic instrumentation and methodol-
ogy leading to the possibility to identify in small quantities of
biological material an entire set of proteins important for the
pathophysiology of a complex disease like COPD [3]. In COPD a
relative low number of proteomic studies has been performed [3],
using different methods [4,5], in biological materials like
bronchoalveolar fluid (BALF) [6–9], induced sputum [10–13]
and exhaled breath condensate [14]. Although promising disease-
specific and severity-related biomarkers came out [4], not one
study focused on the very first phase of the induction of COPD.
In the past, investigating the acute response to cigarette smoking
has been put forward as an attractive approach to understand the
pathogenesis of COPD [15,16]. This so called acute smoking
model is attractive because inflammatory responses of the lung to
cigarette smoke can be investigated in a standardised and dynamic
way. Although highly standardised, the acute smoking results in
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human studies demonstrate remarkably high inter-individual
differences to cigarette smoking [16,17]. This variation may be
due to methodological issues of assessing inflammatory responses,
however, it could also reflect a really different response between
individuals. In this perspective, it is important to acknowledge that
only 20–30% of the smokers develop COPD, suggesting that a
specific genetic background plays a role in the pathogenesis of
COPD [18]. Indeed previous studies have suggested that family
members of patients with severe early-onset COPD have an
increased risk to develop COPD with smoking [19], and can
therefore be labelled as ‘‘susceptible individuals’’. Thus far the
mechanisms that lead to development of COPD in susceptible
smokers remain largely unknown.
In this study we hypothesize that the acute smoking model is an
attractive tool to better understand the essential differences
between susceptible and non-susceptible individuals. This will
especially be important in young individuals with a low number of
pack-years smoking since they still have clean and uncompromised
lungs. In other words, we hypothesize that ageing and lifelong
smoking leads to altered airways not reflecting the very first
aberrant response to cigarette smoking at young age. For this
reason, we set out to investigate the onset of COPD in an acute
smoking experiment in young healthy individuals, being suscep-
tible’’ or ‘‘non-susceptible’’ to develop COPD. To address this
point, we profiled proteins in epithelial lining fluid (ELF), prior to
and 24 h after a controlled smoking episode in susceptible and
non-susceptible young individuals. In addition, we compare these
results with those in older subjects with established COPD. We
chose to investigate ELF because this biologically active fluid
constitutes the very first barrier to cigarette smoke, and because
proteomic analysis of undiluted ELF recovered by a bronchoscopic




This study was part of a larger multi-centre study (www.
clinicaltrials.gov, NCT00807469) [21]. Subjects were recruited at
the outdoor clinic of the University Medical Centre Groningen
(UMCG). Young (18–45 years) subjects were divided in those who
were susceptible or not susceptible to develop COPD. Suscepti-
bility was based on family history: not susceptible refers to subjects
with smoking family members who are at least 45 years old yet
without having COPD. Susceptible individuals needed to have a
high prevalence of COPD in smoking family members older than
45 years: 2 out of 2, 2 out of 3, 3 out of 3, 3 out of 4, or 4 out of 4.
All subjects were ‘‘party smokers’’ with ,10 pack-years smoking,
who were able to stop smoking for at least two days and start
smoking on request. Old (.45 years) subjects with established
COPD (GOLD II) and . 10 pack-years smoking were included
for comparison. In addition, two control groups of old individuals
were included: subjects with normal lung function despite . 10
pack/years smoking (healthy smokers), and subjects with normal
lung function and no smoking history (healthy non-smokers).
The study was approved by the Medisch Ethische Commissie
Universitair Medisch Centrum Groningen (METc 2008–136), and
all subjects gave their written informed consent.
Smoking, Elf Collection and Sample Preparation
Young susceptible and non-susceptible individuals and old
COPD patients participated in the acute smoking experiments.
The healthy smoking and non-smoking individuals did not
perform smoking experiments and served as controls for COPD
patients at baseline. All subjects were not allowed to smoke for at
least two days prior to the experiments. Immediately before
smoking exhaled CO was measured to ascertain that individuals
had not smoked recently, and immediately after smoking to
confirm that all individuals inhaled cigarette smoke sufficiently. If
subjects had an exhaled CO .5 ppm, indicating recent cigarette
smoking, they were not allowed to participate in the acute smoking
experiment. In the acute smoking experiment, all subjects smoked
3 Marlboro cigarettes within one hour under supervision; always
at the same time of the day between 9 and 11 A.M. Data from
subjects who did not inhale sufficiently (exhaled CO ,2 ppm) was
not included. Bronchoscopy was performed both 24 hours after
smoking and 6 weeks later in a stable phase to obtain baseline
data. All bronchoscopies were carried out according to interna-
tional guidelines [22]. ELF was collected at the mucosa of the left
main bronchus using 3 microsampling probes (BC-401C; Olym-
pus, Tokyo, Japan) [23].
Stable Isotope Labelling
ELF samples containing 50 mg total protein were used for
iTRAQ labelling. The procedure was performed as previously
described [24,25]. Briefly, each tryptic digested sample was
labelled (iTRAQ Reagent 4-plex, ABSciex, Foster City, CA,
USA) according to the manufacturer’s protocol. The individually
labelled digests were then combined into a single sample mixture
and subjected to strong-cation exchange chromatography (AKTA
Purifier, GE Healthcare Biosciences AB, Uppsala, Sweden). The
resulting peptide-containing fractions were separated by reversed-
phase chromatography (Ultimate 3000 nanoflow liquid chroma-
tography system, Dionex, Amsterdam, The Netherlands). Frac-
tions of 12 sec were spotted on MALDI targets (Probot, Dionex,
Amsterdam, The Netherlands) and mass spectrometric analysis
was carried out on a 4800 Proteomics Analyzer MALDI TOF/
TOF instrument (Applied Biosystems, Foster City, CA, USA)
controlled by the 4000 Series Explorer v3.5 software.
Proteins were identified using Protein Pilot software v4.0
(Applied Biosystems). The identification was performed using the
IPI Human database (IPI v3.83). The Protein Pilot cut-off score
was 1.3, corresponding to a confidence limit of 95% at the peptide
level. Protein identifications were based on at least 2 unique
peptides identified independently. A probability higher than 95%
and a false discovery rate lower than 5%, were accepted. The
experiments were repeated with the same set of samples.
ProQuant software was used to calculate the intensity of 3
reporter ions (m/z: 115, 116 and 117, Figure 1) and to divide
them by the intensity of the 4th reporter ion (m/z: 114) for each
measured compound. All ratios were transformed into natural
logarithms and plotted against the number of peptides subjected to
MS/MS analysis. Gaussian curves were fitted on the smoothed
histograms (histogram between 21 and +1 with 200 steps,
smoothed using a Savitzky-Golay algorithm) and standard
deviations (SD) were determined. Proteins with natural log-
transformed ion ratios differing by at least 2.56SD (98.8%
confidence) were considered significantly different from the
random variation. Visual explanation of the applied method is
presented in Figure S1 in the File S1. All data pre-processing
work was done on a personal computer equipped with a
+3600 MHz AMD processor and 4 GB of RAM, using MATLAB
7.11.0.584 (R2010b).
ELISA
Due to methodological problems with the commercially
available ELISA kits, we were unable to obtain results for
S100A8 and ALDH3A1. The other four selected proteins were all
Susceptibility to COPD and Acute Smoke Exposure
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above the detection limit of the ELISA. Commercially available
ELISA kits from Uscn Life Science Inc. (China) were used
following the manufacturer’s protocols. Briefly, 100 uL of undi-
luted ELF were incubated for 2 hours at 37uC in microtitre plates
precoated with the specific monoclonal antibody. Subsequently a
biotin-conjugated polyclonal antibody was added, followed by a
TMB substrate solution and finally the reaction was stopped
adding 50 uL of a sulphuric acid solution. The absorbance of each
sample and calibration curve was read at 450 nm. The protein
concentration in the samples was determined comparing the
absorbance values of the samples to the standard curve.
Statistical analyses were performed using SPSS (version 16.0;
SPSS, Chicago IL). Baseline differences between young non-
susceptible versus young susceptible individuals and between old
healthy smokers versus non-smokers and COPD were tested using
Mann-Whitney U tests. Changes associated with smoke exposure
(before and after acute exposure to cigarette smoke) within the
group of young non-susceptible individuals, young susceptible
individuals and COPD patients were tested using Wilcoxon tests.
P-values , 0.05 were considered statistically significant.
Immunohistochemistry
Immunohistochemistry of Aldehyde dehydrogenase 3A1 was
performed to compare lung tissue from COPD patients who
underwent lung transplantation (5 current smokers and 5 ex-
smokers) and non-COPD controls who underwent surgery for lung
cancer (5 current smokers and 5 never/ex-smokers). Three-mm
thick lung sections were cut from selected formalin-fixed paraffin-
embedded tissue blocks; immunostaining and quantification was
performed as previously described [26]. Anti-ALDH3A1,
SAB1405446 (Sigma-Aldrich Chemie BV, Zwijndrecht, The




A total of 25 subjects were selected for the iTRAQ experiments,
5 participants per group (Table 1 upper section). There was no
significant difference in the clinical characteristics between the
young susceptible and non-susceptible subjects, although there was
a trend for higher age in the former group (p = 0.16). COPD
patients had a higher age than the old healthy smokers and non-
smokers (p = 0.009 and p= 0.006, respectively). The COPD
patients demonstrated airway obstruction compatible with GOLD
stage II and 6 (out of 8) subjects demonstrated signs of emphysema
(CO diffusion , 80% predicted). To verify the proteins detected
by iTRAQ, eighteen additional subjects divided over the above
groups were additionally included to enhance the numbers in the
ELISA experiments, resulting in a total of 43 participating subjects
(Table 1 lower section).
Proteomics
General results. Pooled ELF samples (n = 5 per group)
labelled with stable isotopes (iTRAQ4-plex) were analysed by mass
spectrometry in duplicate (Table S1–S2 in File S1). In the group
of young subjects 64 overlapping proteins were identified; in the
older group 70 proteins (Figure S2 in File S1). At baseline, 6
Figure 1. Reporter ion pattern of Peroxiredoxin I (peptide LVQAFQFTDK). Peaks at 114, 115, 116 and 117 represent the group of young
non-susceptible after acute smoking; young non-susceptible at baseline, young susceptible after acute smoking and young susceptible at baseline,
respectively.
doi:10.1371/journal.pone.0102037.g001
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overlapping proteins were differentially expressed between young
susceptible and young non-susceptible individuals; and 7 between
old healthy smokers and never-smokers (Table S3 and figure S3
in File S1). After acute smoking of 3 cigarettes, the number of
differentially expressed proteins showing overlap between the first
and second experiment was 9 proteins in the group of the young
susceptible individuals, 3 in the young non-susceptible individuals
and 3 in the COPD patients (Table S4 and figure S4 in File
S1).
The complete list of all proteins and relative peptides identified
and quantified with high confidence (.95%) is reported in Table
Data S1.
Proteomics: selection of differential proteins. The fol-
lowing proteins were selected for further analysis with ELISA or
immunohistochemistry based on the following criteria: 1) signif-
icant up- or down-regulation in both iTRAQ experiments, 2)
quantification with 2 or more statistically significantly different
peptides (p value , 0.02), 3) biological function that might be
implicated in the onset and progression of COPD.
N Peroxiredoxin I (accession number Q06830),
N Uteroglobin (CC16, Clara Cell 16, accession number P11684),
N SerpinB3 (SCCA1, accession number P29508),
N S100A8 (MRP8, Calgranulin A, accession number P05109),
N S100A9 (MRP14, Calgranulin B, accession number P06702),
N Aldehyde dehydrogenase 3A1 (ALDH3A1, accession number
P30838).
Proteomics: comparison between groups at
baseline. There were no significant differences in Peroxire-
doxin I, Uteroglobin and ALDH3A1, between young susceptible
and young non-susceptible individuals, while SerpinB3, S100A9,
Table 1. Characteristics of the participating subjects.









A. Subjects participating in the iTRAQ study
Male/Female, n 3/2 0/5 0/5 3/2 1/4
Age, years 29 (18–42) 20 (19–39) 66 (55–74) 50 (47–53) 49 (45–53)
Pack years, n 0 (0–8) 2 (0–9) 23 (21–46) 38 (11–52) 0
FEV1, % pred 103 (97–108) 109 (98–117) 74 (49–80) 111 (105–32) 111 (109–122)
FEV1/FVC, % 80 (76–94) 81 (77–91) 54 (32–60) 80 (74–85) 76 (75–82)
TLC, % pred 25 (23–28) 22 (16–25) 39 (38–55) 36 (32–37) 33 (31–36)
CO diffusion, mmol/min/kPa 84 (80–97) 87 (62–98) 71 (40–86) 84 (74–96) 106 (84–117)
B. Subjects participating in the ELISA study
Male/Female,n 3/4 0/6 0/8 6/3 8/5
Age, years 29 (18–42) 21 (19–39) 66 (55–74) 54 (47–70) 54.5 (45–70)
Pack years, n 0 (0–8) 2 (0–9) 28 (20–49) 39 (11–52) 0
FEV1, % pred 108 (100–116) 109 (98–117) 68 (49–80) 110 (101–121) 111 (93–122)
FEV1/FVC, % 78 (76–94) 82 (77–91) 52 (32–60) 78 (70–85) 78 (74–82)
TLC, % pred 25 (23–28) 22 (16–25) 38.5 (33–55) 36 (32–41) 36 (31–43)
CO diffusion, mmol/min/kPa 85 (84–102) 88 (62–98) 64 (40–91) 88 (83–117) 106 (84–119)
Values are medians (ranges) or numbers.
doi:10.1371/journal.pone.0102037.t001
Table 2. Summary of iTRAQ comparisons from pooled ELF samples.







Old healthy smokers vs
never-smokers
Peroxiredoxin I 0.29 0.50 6.9 s ,2.5 s ,2.5
Uteroglobin s ,2.5 0.50 0.1 s ,2.5 s ,2.5
SerpinB3 s ,2.5 0.40 11.6* 2.42 s ,2.5
S100A9 0.39 0.50 s ,2.5 3.51 s ,2.5
S100A8 0.35 0.46 s , 2.5 2.93 s ,2.5
ALDH3A1 0.29 0.29 16.7 s ,2.5 7.80
Data are expressed as median of ratios (of peptides for one protein that are discriminatory between samples): after smoking/before smoking (left section) or group
comparisons (right section). s ,2.5: peptides of that protein did not reach a statistically significant difference. *: based on one peptide.
doi:10.1371/journal.pone.0102037.t002
Susceptibility to COPD and Acute Smoke Exposure
PLOS ONE | www.plosone.org 4 July 2014 | Volume 9 | Issue 7 | e102037
Susceptibility to COPD and Acute Smoke Exposure
PLOS ONE | www.plosone.org 5 July 2014 | Volume 9 | Issue 7 | e102037
and S100A8 levels were higher in the young susceptible group
(Table 2). Old healthy smokers showed higher levels of
ALDH3A1 and Peroxiredoxin I than old healthy non-smokers.
Proteomics: comparison before and after acute
smoking. In the young susceptible individuals levels of Perox-
iredoxin I, S100A9, S100A8 and ALDH3A1 decreased after acute
smoke exposure (Table 2) while all selected proteins were down-
regulated in the young non-susceptible group. On the contrary,
Peroxiredoxin I, SerpinB3, and ALDH3A1 were up-regulated in
the old COPD patients, whereas Uteroglobin was down-regulated
after acute smoke exposure (Table 2).
ELISA: comparison between groups at baseline. Young
susceptible individuals showed a trend for lower SerpinB3
concentrations in ELF than young non-susceptible individuals
(p = 0.056).There were no significant differences between old
healthy smokers versus non-smokers, nor between COPD patients
and the two old healthy groups.
ELISA: comparison before and after acute smoking. In
young susceptible individuals, expression of the selected proteins
did not differ significantly before and after acute smoking
(Table 3). In the young non-susceptible individuals Peroxiredoxin
I and S100A9 concentrations were lower after smoking (p = 0.043,
and p=0.028, respectively), whereas SerpinB3 showed a similar
trend (p= 0.08) (Figure 2).The comparison between young non-
susceptible and susceptible individuals regarding their acute
smoking response showed a significant difference in the change
of SerpinB3 with smoking (Table 3, Mann Whitney U test,
p = 0.016). In the COPD patients Peroxiredoxin I tended to
increase after acute smoking (p = 0.063).
Due to experimental issues no quantifiable results were obtained
for S100A8 (Table S6 in File S1); regarding ALDH3A1 no
statistically significant differences between the groups were
observed (Table S7 in File S1).
Immunohistochemistry confirmation: ALDH3A1. A
semi-quantitative analysis was performed in a blinded fashion
(by authors LF and ML) on ALDH3A1 expression in lung
resection material of 5 COPD patients (current smokers), 5 COPD
patients (ex-smokers), 5 healthy controls (current smokers), and 5
healthy never/ex-smokers (Table S5 in File S1). ALDH3A1
protein expression was clearly associated with smoking status
(Figure S5 in File S1). Highest expression of ALDH3A1 was
observed in macrophages and epithelial cells of COPD patients
(current smokers), followed by healthy subjects (current smokers),
and COPD patients (former smokers). The lowest expression was
seen in healthy individuals and never smokers (Figure 3).
Discussion
This is the first study to apply an unbiased proteomic approach
to better understand the mechanisms underlying the development
of COPD. iTRAQ analysis of ELF after acute smoke exposure
demonstrated (in duplo) 9 proteins to be increased or decreased in
young susceptible individuals, 4 proteins in the young non-
susceptible individuals, and 3 in COPD patients. Six proteins were
selected based on significant up- or down-regulation in two
iTRAQ experiments, identification and quantification with two or
more statistically significant peptides, and a biological function
that might be implicated in the onset and progression of COPD.
Of interest, two proteins (SerpinB3, Uteroglobin) decreased after
smoking of 3 cigarettes in young non-susceptible individuals while
remaining stable in young susceptible individuals. Four proteins
(Peroxiredoxin I, S100A9, S100A8, ALDH3A1) decreased both in
young susceptible and non-susceptible individuals. Peroxiredoxin,
SerpinB3 and ALDH3A1 increased in COPD patients after a
comparable smoke exposure. These differentially expressed
proteins may play a role in protection against oxidative stress,
anti-inflammatory responses and metabolizing toxic compounds,
thus constituting plausible candidates involved in COPD devel-
opment.
What might be the function of the above described differential
proteins in relation to COPD more specifically? SerpinB3 inhibits
several types of proteases and plays a role in modulating
inflammation, programmed cell death and fibrosis [27]. S100A8
and S100A9 proteins, so called calgranulins, are known for their
antimicrobial activity and their role as pro-inflammatory media-
tors in acute and chronic inflammation [28–30]. Uteroglobin may
play a role in reducing airway inflammation and protecting against
Figure 2. ELISA results of individual epithelial lining fluid (ELF) samples of young susceptible individuals, young non-susceptible
individuals, and established COPD patients, before and after acute smoking. Results are given in box-plots with medians and interquartile
ranges. *: p,0.05 before vs after smoking, ‘: p,0.05 vs young susceptible individuals at baseline.
doi:10.1371/journal.pone.0102037.g002
Table 3. ELISA results of non-pooled ELF.
Acute smoking experiment Baseline controls





Peroxiredoxin I, pg/mL Before 28.5 (3.3–268) 105 (21–473) 3.8 (0.4–8.8) 36.5 (1.8–227) 13 (1.1–164)
Peroxiredoxin I, pg/mL After 10.5 (0.07–48) 10.5 (1.9–15.5)* 10.8 (2.4–39)‘
Uteroglobin, pg/mL Before 176 (100–933) 415 (29–1123) 24 (21–52) 409 (17–1484) 134 (29–764)
Uteroglobin, pg/mL After 195 (21–580) 81 (25–1115) 84 (54–166)
Serpin B3, pg/mL Before 1536 (417–5152)# 4803 (1900–9371) 3745 (567–9254) 3935 (798–4454) 2476 (821–4904)
Serpin B3, pg/mL After 2609 (1040–3439) 2210 (1610–2955) 2907 (1398–7474)
S100 A9, mg/mL Before 0.24 (0.01–0.96) 0.43 (0.17–2.80) 0.63 (0.37–0.87) 0.9 (0.2–5.2) 1 (0.3–2.2)
S100 A9, mg/mL After 0.72 (0.22–0.75) 0.18 (0.05–0.39)* 0.54 (0.10–1.90)
Values are medians (ranges).*p,0.05 vs before. ‘p= 0.063 vs before. Bold: significant difference in acute smoke response between two groups. #p= 0.056 vs young
non-susceptible subjects. Old healthy smokers and never-smokers did not perform smoking experiments.
doi:10.1371/journal.pone.0102037.t003
Susceptibility to COPD and Acute Smoke Exposure
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oxidative stress, in addition to its immunosuppressive and anti-
tumor qualities [31]. Peroxiredoxins are known to control the
response to oxidants and to play an anti-inflammatory role [32].
They are highly expressed in the healthy lung [28], and constitute
a powerful defence against oxidative stress by decomposing
peroxides, one of the major components of the tar phase of
cigarette smoke. Finally, ALDH3A1 is one of the aldehyde
dehydrogenases involved in the detoxification of carcinogenic
aldehydes associated with cigarette smoke [33].
We found four proteins to decrease upon acute smoking
irrespective of COPD susceptibility and hypothesize that these
proteins play a role in orchestrating the normal inflammatory
response to smoke exposure. In contrast, SerpinB3 and Uter-
oglobin decreased exclusively in young non-susceptible individu-
als, and ELISA experiments confirmed this for SerpinB3. The
differential SerpinB3 and Uteroglobin response on smoking
between the two young groups suggests that these proteins might
be crucial for the very first steps towards COPD, given its
modulatory function in inflammation and fibrosis [27] and release
of lysosomal proteinases from damaged epithelial cells [34].
SerpinB3 concentrations have been shown to be higher in
bronchoalveolar lavage fluid of smokers than non-smokers [35].
It was therefore an unanticipated observation that the expression
of this protective protein was not restored to baseline 24 hours
after acute smoke exposure in non-susceptible individuals, in
contrast to the susceptible individuals. Whether this finding in ELF
is a negative mirror of what occurs in the airway wall after an
attack of cigarette smoking needs to be determined in further
studies. In that case a lower value in ELF in non-susceptible
youngsters indicates an increased use in the lung tissue, whereas
this does not occur in susceptible individuals. Uteroglobin or
human Clara cell protein (CC16) is a 15.8-kDa homodimeric
protein secreted in large amounts into the airways by the non-
ciliated bronchiolar Clara cells. The exact physiological function
in the lung is not known, but it likely plays a role in reducing
airway inflammation and protecting against oxidative stress, in
addition to immunosuppressive and anti-tumor qualities [31]. In
an acute smoke model in rats a dose dependent increase in serum
Uteroglobin was demonstrated with a peak level 2 hours after
smoking and a return to normal levels after 24 hours [36]. Our
results show a decrease of Uteroglobin only in young non-
susceptible individuals 24 hours after smoking. Unfortunately, we
have no information about its presence immediately after smoking,
so future studies, using less invasive sampling techniques, are
Figure 3. Immunohistochemistry of aldehyde dehydrogenase 3A1. Panel A: immunostaining of a COPD patient current smoker. Panel B:
immunostaining of a healthy control current smoker. Panel C: immunostaining of a COPD patient ex-smoker. Panel D: immunostaining of a healthy
control non-smoker. All COPD patients are GOLD STAGE II. The red arrows indicate epithelial cells and blue arrows indicate macrophages, more or less
positive for ALDH3A1.
doi:10.1371/journal.pone.0102037.g003
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needed to understand its complete time-response. COPD patients
demonstrated an opposite response to acute smoking compared
with young susceptible and non-susceptible individuals, with
higher expression of Peroxiredoxin I, SerpinB3, and ALDH3A1
after smoking. This finding supports our choice of studying young
individuals for better understanding of the very first steps of
COPD induction. Apparently, the bronchial tree in COPD
patients has changed dramatically after many years of smoking
and is able to up-regulate these mainly protective proteins for at
least 24 hours after smoke inhalation.
To assess if the detected proteins in COPD reflect a nonspecific
response to chronic smoking or rather are a disease-specific
characteristic we compared healthy smokers and never-smokers (at
baseline). The iTRAQ and immunohistochemistry results of
ALDH3A1 clearly show that this protective protein is strongly
up-regulated due to chronic smoking both in COPD and healthy
smokers. Interestingly, one proteomic study demonstrated in-
creased levels in BAL fluid from ex-smoking COPD patients [8].
Regarding Uteroglobin we expected to find a smoking-induced
reduction as chronic smoking has been associated with a lower
number of Clara cells in the bronchial tree [37] as well as with
lower levels in BAL fluid [38–41]. Moreover, reduced Uteroglobin
protein levels have been demonstrated in BAL [41] and serum
[41,42] of COPD patients, whereas severe COPD patients
demonstrated lower levels in sputum than moderate COPD
patients [43]. In line, 2 proteomic studies demonstrated decreased
levels in BAL fluid of asymptomatic smokers [40] and in induced
sputum of smokers and COPD patients [12]. Our ELISA results
indeed demonstrated reduced levels in ELF of COPD patients; a
finding that did not match with the iTRAQ results in healthy
smokers and never smokers.
A possible weakness of our study is that susceptibility at young
age to develop COPD was based on family history. On the other
hand, this strategy has been used in previous studies as well and
provided clues for a genetic component of the disease [19,44–46].
A second limitation is that we included a relatively low number of
participants, and the groups were not optimally balanced for age
and gender, which poses questions regarding the generalization of
the obtained results. Third, the iTRAQ samples of the different
groups needed to be pooled which allowed only 5 comparisons.
On the other hand ELISA was performed on individual samples
from a larger group of participants and was not limited in the
number of comparisons. Despite the above described methodo-
logical drawbacks, our study was able to show statistically
significant differences, suggesting major changes. The observed
differential proteomic profiles in susceptible and non-susceptible
individuals open avenues for further biomarker development in
larger studies.
In conclusion, we describe one of the first studies to assess
proteins associated with susceptibility to develop COPD using an
unbiased approach. We found statistically significant changes in
expression of candidate proteins upon acute smoke exposure, by
studying two young cohorts of individuals and a group of older
COPD patients. Our data show that already at young age, subjects
with a positive family history of COPD respond differently to
cigarette smoke than those with a negative family history.
Particularly SerpinB3 and Uteroglobin were found to be proteins
that may play a role in the development of COPD.
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